TBA-7371 is primarily investigated for its application in the treatment of tuberculosis (TB), particularly drug-resistant strains. It functions as a selective inhibitor of the bacterial enzyme DprE1, which is essential for the biosynthesis of the mycobacterial cell wall. By targeting DprE1, TBA-7371 disrupts the cell wall formation, leading to the death of Mycobacterium tuberculosis. This makes it a promising candidate for inclusion in TB drug regimens, especially in cases where traditional antibiotics like rifampicin and isoniazid are ineffective. Its development is part of ongoing efforts to address the global challenge of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Clinical trials are underway to evaluate its efficacy, safety, and potential for combination therapy with other anti-TB agents.